Just out: Mayo Clinic mSMART Risk Stratification of Myeloma #EHA25 1/ We recommend and use same high risk cytogenetic definition as the latest IMS/IMWG paper 2/ Primary plasma cell leukemia is high risk myeloma 3/ We define Double-hit high risk myeloma msmart.org/mm-treatment-g…

‼️ #EHA2025 #JCO simultaneous publication by Joshua Zeidner MD et al: Azacitidine, Venetoclax and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged Acute Myeloid Leukemia: brnw.ch/21wTlXR

Game Changer in GVHD: Post-Transplant Cyclophosphamide Boosts Survival After Matched Donor SCT Summary: In a randomized trial of patients undergoing allogeneic stem cell transplantation (SCT) from matched related donors, post-transplant cyclophosphamide plus cyclosporin

Blina Beneath the Skin: Subcutaneous Dosing Shows Promise in Tough-to-Treat B-ALL Summary: In a phase 1/2 trial, subcutaneous blinatumomab demonstrated encouraging efficacy and manageable safety in adults with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL).

New in ESMO GI Onc- Managing adverse events in patients with metastatic colorectal cancer receiving trifluridine/tipiracil in combination with bevacizumab. Dr. Marwan G. Fakih et al 📄 Practical guidance for managing key AEs with Lonsurf+Bevacizumab. 🩸 Neutropenia 💢 Hypertension 💊

📌 Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer: ASCO Guideline Clinical Insights✨ ascopubs.org/doi/10.1200/OP… 👉🏻 Why Omit SLNB? Balancing Benefits Versus Potential Harms 👉🏻 How Does SLNB Impact Radiation Therapy Decisions? 👉🏻 How Does SLNB Omission Impact Systemic

Nivo-AVD is the new R-CHOP for Hodgkin's ⁦Journal of Clinical Oncology⁩ ascopubs.org/doi/10.1200/JC…

What’s up with Beta 2 microglobulin (B2M) and myeloma? Why is it the sole non-cytogenetic marker used in the new IMWG high risk definition? Why does it matter whether the creatinine is high or not? Thread 1/

🚨 GI Cancer Mortality to Double by 2050📊 ESMO GI 2025 shows sharp rise in deaths due to: 🔹 Colorectal: +103% 🔹 Pancreatic: +100% 🔹 Esophageal: +86% 🔹 Liver: +81% 🌍 Biggest increases in Asia & Africa 💡 Call to action: Early detection, access, equity. Time for GI oncologist

It's easy to recommend exercise for better overall health but I had a truly remarkable day in clinic empowering patients with colon cancer to follow an evidence-based, post-op fitness program that offers a survival benefit on par with some chemo drugs Bodies in motion, indeed!

What is resectable , borderline resectable and unresectable Gall bladder cancer . Nice slide by Dr Gonzalo ESMO - Eur. Oncology #ESMOGI2025

🚨 New Insights on #ProstateCancer Care! 📊 Study from ACTREC & TMH Mumbai Treatment expenditures & survival outcomes in mCRPC. Findings: ARPI shines 📉 mOS 17.1 vs 14.1m Docetaxel still cost effective💉 Lu-PSMA for the affordable.🏪(USD 173 and mOS 26.9m vs USD 65 and 14.5m)

Rx of unfit patients with AML: Keeping up with the recent advances #amlsm nature.com/articles/s4140…

IMvigor011 𝗰𝘁𝗗𝗡𝗔+ → 𝗢𝗦/𝗣𝗙𝗦 𝗯𝗲𝗻𝗲𝗳𝗶𝘁 𝘄𝗶𝘁𝗵 𝗮𝘁𝗲𝘇𝗼 𝗰𝘁𝗗𝗡𝗔– → 𝘀𝗽𝗮𝗿𝗲𝗱 𝘂𝗻𝗻𝗲𝗰𝗲𝘀𝘀𝗮𝗿𝘆 𝗜𝗢 Primum non nocere: treating only those with molecular evidence of disease. This is Huge! Congrats to Tom Powles and everyone involved 👏

KEYNOTE-585 Fails While Matterhorn Succeeds in Gastric Cancer: What Lessons Can We Learn? | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…

Infections in cancer. Addressed 10 key issues. Tata Memorial Hospital ACTREC-TMC Vanita Noronha, MBBS MD DM Dr Amol Akhade Amol Patel Nikita Mehra Pramesh CS Ind J Med Ped Oncology Bhausaheb Bagal bhawna sirohi Aju Mathew ecancer.org/en/journal/art…

Tata Memorial Hospital Tata Memorial Centre, Varanasi (MPMMCC & HBCH) HBCHRC,VIZAG - TATA MEMORIAL CENTRE Homi Bhabha Cancer Hospital & Research Centre CCE, TMC-Cancer registries ACTREC-TMC entire TMC family deeply saddened by untimely demise of our alumnus, India’s most illustrious pathologist, Dr Anita Borges. Huge loss to oncology fraternity & patients. Family & friends in our prayers

Advances in Myeloma. 2025 Edition Key takeaways from #IMS25 1) Early intervention is here: Given recent EU approval of daratumumab for high risk smoldering myeloma in Europe, and NCCN category 1 recommendation in the US, ~55% of the attendees would offer early intervention

Oncologists: “≥30% shrinkage = response ✅” Tumors: “29% 😏” Who else feels RECIST rules were written just to troll us? 🤔👇 Drop your favorite RECIST frustrations below ⬇️ #OncoTwitter #MedTwitter OncoAlert

Thrilled to share our phase III randomized controlled trial thst demonstrates improved survival by adding platinum based chemotherapy to treat patients with triple negative breast cancer. A step forward in a challenging disease! #BreastCancer #TNBC ascopubs.org/doi/10.1200/JC…